Document is current
Any future updates will be listed below
-
Authors
Xu, Hairong
Wu, Po-Kuei
Ye, Zhaoming
Fan, Zhengfu
Li, Tao
Chen, Tom Wei-Wu
Shen, Jingnan
Yan, Wangjun
Achiwa, Issei
Yoh, Kazukoh
Kikumori, Kunika
Hiruma, Yoshiharu
Greenberg, Jonathan
Niu, Xiaohui
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04488822 at ClinicalTrials.govDocuments that mention this clinical trial
A Phase 3 Study of the Efficacy and Safety of Pexidartinib in East Asian Patients with Tenosynovial Giant Cell Tumor
https://doi.org/10.1007/s40487-025-00365-z
-
Funding
Funding for this research was provided by:
This study was funded by Daiichi Sankyo, Inc.
- License Information
-
More Information
Article History
Received: 7 April 2025
Accepted: 17 July 2025
First Online: 21 August 2025
Declarations
:
: Hairong Xu: no conflicts to disclose. Po-Kuei Wu: no conflicts to disclose. Zhaoming Ye: no conflicts to disclose. Zhengfu Fan: no conflicts to disclose. Tao Li: no conflicts to disclose. Tom Wei-Wu Chen: no conflicts to disclose. Jingnan Shen: no conflicts to disclose. Wangjun Yan: no conflicts to disclose. Issei Achiwa: employee of Daiichi Sankyo Co., LTD. Kazukoh Yoh: employee of Daiichi Sankyo Co., LTD. Kunika Kikumori: employee of Daiichi Sankyo Co., LTD. Yoshiharu Hiruma: employee of Daiichi Sankyo Co., LTD. Jonathan Greenberg: employee of Daiichi Sankyo Inc. Xiaohui Niu: no conflicts to disclose.
: All study documents were approved by the sites’ independent ethics committees or institutional review boards. The study was conducted in compliance with the ethical principles of the Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, and Good Clinical Practice guidelines. All patients provided written informed consent.
